Finoriq research workspace
Annexon, Inc. (ANNX) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Annexon, Inc. (ANNX).
Company Snapshot
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
- Company
- Annexon, Inc. (ANNX)
- Ticker
- ANNX
- Market Cap
- $917.5M
- Latest Price
- $5.60
- Industry
- Biotech & Pharma
Annexon, Inc. (ANNX) Recent Insider Transactions
Recent market insider transaction records indexed for Annexon, Inc. (ANNX).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| Carson William H.Common Stock | P | Acquired | $49,600 | 2026-04-10 |
| Carson William H.Common Stock | P | Acquired | $45,360 | 2026-03-10 |
| ARTIS DEAN RICHARDEVP & CHIEF SCIENTIFIC OFFICER | S | Disposed | -$32,004 | 2026-03-02 |
| Yednock TedEVP & CHIEF INNOVATION OFFICER | S | Disposed | -$30,168 | 2026-03-02 |
| Overdorf MichaelEVP & CHIEF BUSINESS OFFICER | S | Disposed | -$23,517 | 2026-03-02 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.